Profile

Noa Therapeutics is pioneering the development of novel small-molecule therapeutics for the tailored treatment of inflammatory diseases involving barrier dysfunction. The company’s suite of singular, non-steroidal, small molecules simultaneously resolves dysregulated immune and barrier transcriptional pathways to address complex unmet needs in >$100B inflammatory barrier disease markets. Starting with a first use case in atopic dermatitis, Noa is actively expanding the pipeline of unique NCEs for secondary indications including ulcerative colitis, and multiple sclerosis.

Noa Therapeutics Inc. logo

Website

noatherapeutics.com

Contact


Event details

Date: November 4 - 6, 2024

Event contact

Rita Patlan
Area Director
Europe: Aerospace and Defence, Environmental Technologies and Infrastructure

Participants

12 in total